Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Eur J Cardiothorac Surg. 2019 Oct 1;56(4):800-806. doi: 10.1093/ejcts/ezz039.
Our goal was to determine the optimal timing and choice of surgical antimicrobial prophylaxis (SAP) in patients having cardiac surgery.
The setting was the Swiss surgical site infection (SSI) national surveillance system with a follow-up rate of >94%. Participants were patients from 14 hospitals who had cardiac surgery from 2009 to 2017 with clean wounds, SAP with cefuroxime, cefazolin or a vancomycin/cefuroxime combination and timing of SAP within 120 min before the incision. Exposures were SAP timing and agents; the main outcome was the incidence of SSI. We fitted generalized additive and mixed-effects generalized linear models to describe effects predicting SSIs.
A total of 21 007 patients were enrolled with an SSI incidence of 5.5%. Administration of SAP within 30 min before the incision was significantly associated with decreased deep/organ space SSI [adjusted odds ratio (OR) 0.73, 95% confidence interval (CI) 0.54-0.98; P = 0.035] compared to administration of SAP 60-120 min before the incision. Cefazolin (adjusted OR 0.64, 95% CI 0.49-0.84; P = 0.001) but not vancomycin/cefuroxime combination (adjusted OR 1.05, 95% CI 0.82-1.34; P = 0.689) was significantly associated with a lower risk of overall SSI compared to cefuroxime alone. Nevertheless, there were no statistically significant differences between the SAP agents and the risk of deep/organ space SSI.
The results from this large prospective study provide substantial arguments that administration of SAP close to the time of the incision is more effective than earlier administration before cardiac surgery, making compliance with SAP administration easier. The choice of SAP appears to play a significant role in the prevention of all SSIs, even after adjusting for confounding variables.
我们的目标是确定心脏手术患者接受外科预防性抗菌治疗(SAP)的最佳时机和选择。
该研究的背景为瑞士手术部位感染(SSI)国家监测系统,其随访率>94%。参与者为 2009 年至 2017 年间在 14 家医院接受心脏手术的患者,手术切口为清洁切口,SAP 采用头孢呋辛、头孢唑林或万古霉素/头孢呋辛联合用药,SAP 时间为切口前 120 分钟内。暴露因素为 SAP 时间和药物;主要结局为 SSI 发生率。我们使用广义加性和混合效应广义线性模型来描述预测 SSI 的效果。
共纳入 21007 例患者,SSI 发生率为 5.5%。与切口前 60-120 分钟给药相比,切口前 30 分钟内给药 SAP 显著降低深部/器官间隙 SSI 的发生率[调整后的优势比(OR)0.73,95%置信区间(CI)0.54-0.98;P=0.035]。与单独使用头孢呋辛相比,头孢唑林(调整 OR 0.64,95% CI 0.49-0.84;P=0.001)但不是万古霉素/头孢呋辛联合用药(调整 OR 1.05,95% CI 0.82-1.34;P=0.689)显著降低了总体 SSI 的风险。然而,SAP 药物之间在深部/器官间隙 SSI 风险方面没有统计学差异。
这项大型前瞻性研究的结果提供了有力的证据,表明在心脏手术时接近切口时给予 SAP 比术前更早给药更有效,使 SAP 给药的依从性更容易。即使在调整了混杂变量后,SAP 的选择似乎在预防所有 SSI 方面也起着重要作用。